About PhenoNet

  PhenoNet, Inc. is a privately held biotechnology company in advanced clinical drug development headquartered in Cambridge, Massachusetts.  PhenoNet is innovating the development and commercialization of Phenogene drugs for treating neurodegenerative diseases such as Alzheimer's and ALS. Phenogene-1, a combination drug regimen (Phenogene-1a and Phenogene-1b) for non-APoE4 genotype subjects with early Alzheimer’s disease stage, and Phenogene-1a for exploring its potential utility in treating mild to moderate ALS subjects. 

PhenoNet is poised to fundamentally change the therapeutic approach for this substantially unmet medical need with a safe drug combination aimed at slowing down or preventing two significant triggers of Alzheimer’s, thereby modifying the course of disease progression.